Impact of ferric carboxymaltose on the evolution of hemoglobin and ECOG performance status in iron-deficient patients with solid tumors: a 3-month follow-up retrospective study

Coussirou, Jean; Debourdeau, Antoine; Stancu, Alexandru; Jean, C.; Azouza, W.; Chanet, B.; Crozals, F. De; Boustany, Rania; Debourdeau, Philippe

doi:10.1007/s00520-018-4250-x

Cited by 5 publications

(4 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In agreement with Steinmetz et al, this trial suggested baseline ferritin levels <100 ng/mL as the predictor of response. Treatment with FCM has also been associated with a significant increase of QoL in patients with various solid tumors [82].…”

Section: Evidence For Iron Treatment In Cancer Anemiamentioning

confidence: 99%

Anemia and Iron Deficiency in Cancer Patients: Role of Iron Replacement Therapy

et al. 2018

View full text Add to dashboard Cite

Anemia in cancer patients is quite common, with remarkable negative impacts on quality of life and overall prognosis. The pathogenesis is complex and typically multifactorial, with iron deficiency (ID) often being a major and potentially treatable contributor. In turn, ID in cancer patients can be due to multiple concurring mechanisms, including bleeding (e.g., in gastrointestinal cancers or after surgery), malnutrition, medications, and hepcidin-driven iron sequestration into macrophages with subsequent iron-restricted erythropoiesis. Indeed, either absolute or functional iron deficiency (AID or FID) can occur. While for absolute ID there is a general consensus regarding the laboratory definition (that is ferritin levels <100 ng/mL ± transferrin saturation (TSAT) <20%), a shared definition of functional ID is still lacking. Current therapeutic options in cancer anemia include iron replacement, erythropoietic stimulating agents (ESAs), and blood transfusions. The latter should be kept to a minimum, because of concerns regarding risks, costs, and limited resources. Iron therapy has proved to be a valid approach to enhance efficacy of ESAs and to reduce transfusion need. Available guidelines focus mainly on patients with chemotherapy-associated anemia, and generally suggest intravenous (IV) iron when AID or FID is present. However, in the case of FID, the upper limit of ferritin in association with TSAT <20% at which iron should be prescribed is a matter of controversy, ranging up to 800 ng/mL. An increasingly recognized indication to IV iron in cancer patients is represented by preoperative anemia in elective oncologic surgery. In this setting, the primary goal of treatment is to decrease the need of blood transfusions in the perioperative period, rather than improving anemia-related symptoms as in chemotherapy-associated anemia. Protocols are mainly based on experiences of Patient Blood Management (PBM) in non-oncologic surgery, but no specific guidelines are available for oncologic surgery. Here we discuss some possible approaches to the management of ID in cancer patients in different clinical settings, based on current guidelines and recommendations, emphasizing the need for further research in the field.

show abstract

Section: Evidence For Iron Treatment In Cancer Anemiamentioning

confidence: 99%

Anemia and Iron Deficiency in Cancer Patients: Role of Iron Replacement Therapy

et al. 2018

View full text Add to dashboard Cite

show abstract

“…In comparison, among the three largest reported series of patients with cancer who received FCM, baseline iron saturation and ferritin levels were only available in 54% to 74% and 54% to 57% of patients, respectively. 7,8,11 Excluding patients who died or received transfusions, all of our patients underwent assessment of haemoglobin levels at the pre-specified intervals in the first 4 weeks. The relative completeness of the data enhanced the study's statistical precision.…”

Section: Discussionmentioning

confidence: 99%

“…7,8 However, previous studies in patients with cancer focused on anaemia with baseline haemoglobin levels of 9 to 11 g/dL. [7][8][9][10][11][12] In addition, the majority of the aforementioned studies assessed the trend of haemoglobin levels at a monthly interval and therefore did not provide much information about haemoglobin levels during the first 4 weeks after treatment.…”

Section: Introductionmentioning

confidence: 99%

Efficacy of Intravenous Iron in Cancer Patients with Moderate to Severe Iron Deficiency Anaemia

Chan

Lee

Tin

et al. 2020

Hong Kong Journal of Radiology

View full text Add to dashboard Cite

“…К настоящему времени поступает все больше доказательств эффективности монотерапии в/в препаратами железа, особенно при использовании более новых соединений третьего поколения [47,48]. Первоначально в трех небольших исследованиях с участием пациенток онкогинекологического профиля, которые получали химиолучевую терапию, зарегистрировано значительное снижение потребности в гемотрансфузиях после применения в/в препарата железа сахарозы [49][50][51].…”

unclassified

Anemia and iron deficiency in cancer patients: the role of intravenous iron supplements (a literature review)

Сакаева¹

2023

J. Mod. Onco.

View full text Add to dashboard Cite

Anemia in patients with malignancies is a common disorder that has a markedly negative impact on quality of life and overall prognosis. The pathogenesis of anemia is complex and multifactorial, depending on the type and stage of malignancy, nutritional status, renal function, age and gender, cytostatic drug, dose, and chemotherapeutic regimen, with iron deficiency often being the main and potentially treatable factor for anemia. In cancer patients, it can be caused by various concomitant mechanisms, including bleeding (e.g., in malignant gastrointestinal tumors or after surgery), malnutrition, medication, and hepcidin-induced iron sequestration in macrophages, with subsequent iron-deficient erythropoiesis. The variety of clinical manifestations of anemia makes it challenging to establish universal criteria to develop optimal treatments. Current therapy for anemia in malignant tumors includes replacement therapy with an iron supplement, erythropoiesis-stimulating agents (erythropoietins), and blood transfusions. However, blood transfusions should be minimized due to the high risks and costs. Therapy with an iron supplement is an effective approach to correcting the iron deficiency. It can increase the efficacy of erythropoiesis-stimulating drugs and reduce the need for blood transfusions. Published guidelines suggest the wide use of intravenous iron supplements. This article discusses possible approaches to treating iron deficiency in cancer patients in various clinical settings. We build on current guidelines and emphasize the need for further research in this area.

show abstract

Impact of ferric carboxymaltose on the evolution of hemoglobin and ECOG performance status in iron-deficient patients with solid tumors: a 3-month follow-up retrospective study

Abstract: Even though there was no improvement in ECOG index, this study did identify an increase of Hb for patients receiving FCM, indicating its potential benefit in iron-deficient cancer patients.

Cited by 5 publications

References 25 publications

Anemia and Iron Deficiency in Cancer Patients: Role of Iron Replacement Therapy

Anemia and Iron Deficiency in Cancer Patients: Role of Iron Replacement Therapy

Efficacy of Intravenous Iron in Cancer Patients with Moderate to Severe Iron Deficiency Anaemia

Anemia and iron deficiency in cancer patients: the role of intravenous iron supplements (a literature review)

Contact Info

Product

Resources

About